ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-Implant Performance of the EC-3 IOL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01333345
Recruitment Status : Unknown
Verified April 2011 by Aaren Scientific Inc..
Recruitment status was:  Enrolling by invitation
First Posted : April 12, 2011
Last Update Posted : April 12, 2011
Sponsor:
Information provided by:
Aaren Scientific Inc.

Brief Summary:
The purpose of this study is to obtain data on the performance of the EC-3 lens at an interval of two years (and beyond) from subjects who were implanted. The primary aim of the study will be to evaluate the presence, if any, of PCO, lens glistening, and other anomalies in the subjects.

Condition or disease
Cataract

Detailed Description:

Anomalies include, but are not limited to:

Posterior Capsule Opacification (PCO) (pathological condition) - delayed clouding of the lens capsule after cataract surgery.

Glistenings - fluid-filled micro-vacuoles that form within the intraocular lens (IOL) optic when the IOL is in an aqueous environment. They may appear to be on the lens surface.

Artifacts - glares, halos, starbursts and/or shadows caused by IOLs.

Fibrosis - the formation of fibrous connective tissue, as in a scar.

Glare - undesirable sensation produced by brightness that is much greater than that to which the eyes are adapted. Causes annoyance, discomfort, or loss in visual performance.

Halos (symptom) - the appearance of hazy ring(s) around light.


Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Post-Implant Performance of the EC-3 IOL ADDENDUM TO THE PROTOCOL: Clinical Evaluation of the EC-3 Hydrophobic Acrylic Posterior Chamber Aphakic Intraocular Lens
Study Start Date : April 2011
Estimated Primary Completion Date : June 2011
Estimated Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract
U.S. FDA Resources




Primary Outcome Measures :
  1. To evaluate the presence, if any, of PCO (Posterior Capsule Opacification) in the EC-3 lens. [ Time Frame: 2-3 years post-implantation ]
    Routine eye exam by the investigator.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who were enrolled in the EC-3 study and implanted with the EC-3 IOL.
Criteria

Inclusion Criteria:

  • Enrollment in the EC-3 clinical trial
  • Subjects who were implanted with EC-3 IOL

Exclusion Criteria:

  • Removal of the EC-3 IOL at any time

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01333345


Locations
United States, Florida
Stephenson Eye Associates
Venice, Florida, United States, 34285
United States, New Hampshire
Eyesight Ophthalmic Services
Dover, New Hampshire, United States, 03820
France
Cabinet d'Ophtalmologie du Dr. Pey
Le Puy en Velay, France, 43000
Sponsors and Collaborators
Aaren Scientific Inc.
Investigators
Principal Investigator: P. Dee G. Stephenson, M.D. Stephenson Eye Associates
Principal Investigator: N. Timothy Peters, M.D. Eyesight Ophthalmic Services PA
Principal Investigator: Christophe Pey, M.D. Cabinet d'Ophtalmologie du Dr. Pey

Responsible Party: Robert Sheehan, VP of Regulatory Affairs & Quality Systems, Aaren Scientific Inc.
ClinicalTrials.gov Identifier: NCT01333345     History of Changes
Other Study ID Numbers: DC-036 Addendum
First Posted: April 12, 2011    Key Record Dates
Last Update Posted: April 12, 2011
Last Verified: April 2011

Keywords provided by Aaren Scientific Inc.:
Cataract replacement surgery
implantation
EC-3 IOL

Additional relevant MeSH terms:
Cataract
Lens Diseases
Eye Diseases